CheckMate 743

CheckMate 743 was a large international clinical trial that compared the combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), against standard chemotherapy as a first-line treatment for unresectable pleural mesothelioma. The trial showed that patients receiving the immunotherapy combination lived longer on average than those receiving chemotherapy, leading to FDA approval of this regimen in October 2020. It was the first major treatment advance for pleural mesothelioma in roughly 16 years.

Origin

The trial was sponsored by Bristol Myers Squibb, the manufacturer of both drugs, and was conducted at sites across multiple countries beginning in 2016. Results were published in The Lancet in 2021 by lead author Paul Baas and colleagues. "CheckMate" is the naming convention BMS uses for its clinical trials of checkpoint inhibitor drugs.

Significance in Asbestos Context

For patients diagnosed with pleural mesothelioma, CheckMate 743 represents a meaningful shift in standard-of-care treatment options and, in many cases, an extension of expected survival. The trial showed median overall survival of about 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy, with the largest benefit seen in patients with non-epithelioid (sarcomatoid or biphasic) histology. This matters for legal claims as well: life-expectancy projections, treatment costs, and damages calculations for medical care and lost future quality of life are all influenced by which treatment regimen a patient receives and how they respond to it. Defense experts may cite CheckMate 743 to argue for longer life expectancy, while plaintiff experts may use it to document the substantial costs and toxicities of modern mesothelioma care.

Example Sentence

After her pleural mesothelioma diagnosis, the oncologist explained that based on CheckMate 743 results, she was a candidate for nivolumab plus ipilimumab rather than traditional chemotherapy.

Related Terms

Pleural Mesothelioma, Immunotherapy, Nivolumab, Ipilimumab, Checkpoint Inhibitor, Epithelioid Mesothelioma

Notes

• Ask your oncologist whether your mesothelioma's histologic subtype (epithelioid, sarcomatoid, or biphasic) affects which first-line regimen is recommended for you. The immunotherapy benefit was strongest in non-epithelioid disease.
• Keep detailed records of all immunotherapy infusions, side effects (especially immune-related adverse events like colitis, pneumonitis, or thyroid problems), hospitalizations, and out-of-pocket costs; these are relevant to damages in any legal claim.
• Ask whether you are eligible for clinical trials building on the CheckMate 743 regimen, including combinations with chemotherapy or newer immunotherapies, which may offer additional options.
• If a defense expert cites CheckMate 743 to argue extended life expectancy, make sure your legal team has your treating oncologist document your individual response, performance status, and prognosis rather than relying on trial averages.